efgartigimod alfa and hyaluronidase (human recombinant) · EFGARTIGIMOD ALFA 200 mg/mL; HYALURONIDASE (HUMAN RECOMBINANT) 2000 U/mL · Injection, Solution · Subcutaneous · argenx US
NDC 73475-1221-01 · 1 SYRINGE, GLASS in 1 CARTON / 5 mL in 1 SYRINGE, GLASS · BLA · View full market →
Only one company currently supplies this market — there is no backup if it stumbles. One of its named manufacturing plants, Catalent Indiana, LLC, failed FDA inspectionwithin the last two years — the agency’s most serious outcome.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 4 quarters since 2024.
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Not scored — fragility is computed for NADAC-priced NDCs.
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
There's no legal definition — it meets 4 of 6 public criteria. Why that matters →
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| argenx US | EFGARTIGIMOD ALFA 180 mg/mL; HYALURONIDASE (HUMAN RECOMBINANT) 2000 U/mL | Jul 15, 2026 | Sep 2, 2026 |
| argenx US | EFGARTIGIMOD ALFA 200 mg/mL; HYALURONIDASE (HUMAN RECOMBINANT) 2000 U/mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "VYVGART Hytrulo — NDC 73475-1221-01," retrieved September 3, 2026, https://drugdashboards.com/drug/73475122101.
Free to cite with attribution — see how the data is put together.